Advertisement

RAPID3, an Index to Assess and Monitor Patients with Rheumatoid Arthritis, Without Formal Joint Counts: Similar Results to DAS28 and CDAI in Clinical Trials and Clinical Care

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pincus T.
        • Swearingen C.J.
        • Bergman M.
        • et al.
        RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to DAS and CDAI categories.
        J Rheumatol. 2008; 35: 2136-2147
        • Saag K.G.
        • Teng G.G.
        • Patkar N.M.
        • et al.
        American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
        Arthritis Rheum. 2008; 59: 762-784
        • van der Heijde D.M.
        • van't Hof M.
        • van Riel P.L.
        • et al.
        Development of a disease activity score based on judgment in clinical practice by rheumatologists.
        J Rheumatol. 1993; 20: 579-581
        • Prevoo M.L.
        • van't Hof M.A.
        • Kuper H.H.
        • et al.
        Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
        Arthritis Rheum. 1995; 38: 44-48
        • Aletaha D.
        • Smolen J.
        The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.
        Clin Exp Rheumatol. 2005; 23: S100-S108
        • Stucki G.
        • Liang M.H.
        • Stucki S.
        • et al.
        A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research.
        Arthritis Rheum. 1995; 38: 795-798
        • Wolfe F.
        • Michaud K.
        • Pincus T.
        A composite disease activity scale for clinical practice, observational studies and clinical trials: the patient activity scale (PAS/PAS-II).
        J Rheumatol. 2005; 32: 2410-2415
        • Yazici Y.
        • Bergman M.
        • Pincus T.
        Time to score quantitative rheumatoid arthritis measures: 28-joint count, disease activity score, health assessment questionnaire (HAQ), multidimensional HAQ (MDHAQ), and routine assessment of patient index data (RAPID) scores.
        J Rheumatol. 2008; 35: 603-609
      1. Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res, in press.

        • Pincus T.
        • Bergman M.J.
        • Yazici Y.
        • et al.
        An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
        Rheumatology (Oxford). 2008; 47: 345-349
        • Pincus T.
        • Strand V.
        • Koch G.
        • et al.
        An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial.
        Arthritis Rheum. 2003; 48: 625-630
        • Pincus T.
        • Chung C.
        • Segurado O.G.
        • et al.
        An index of patient self-reported outcomes (PRO index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis.
        J Rheumatol. 2006; 33: 2146-2152
        • Neogi T.
        • Felson D.
        • Niu J.
        • et al.
        The association between radiographic features of knee osteoarthritis and pain: results from two cohort studies.
        BMJ. 2009, Aug 21; ([Epub ahead of print])